Press release
Dry Age-related Macular Degeneration Pipeline Report 2024 - Clinical Trials, FDA, EMA, & PMDA Approvals, Drugs, Therapeutic Analysis, and Companies by DelveInsight
Dry Age-related Macular Degeneration Pipeline
DelveInsight's 'Dry Age-related Macular Degeneration Pipeline Insight 2024' report provides comprehensive global coverage of available, marketed, and pipeline Dry Age-related Macular Degeneration therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Dry Age-related Macular Degeneration pipeline domain.
For Dry Age-related Macular Degeneration emerging drugs, the Dry Age-related Macular Degeneration pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
To know more in detail about Dry Age-related Macular Degeneration pipeline insight, click here: https://www.delveinsight.com/report-store/dry-age-macular-degeneration-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Dry Age-related Macular Degeneration Overview
Age-related Macular Degeneration (AMD) is a degenerative disease of the ocular-posterior segment's center (the macula lutea) that causes slow degeneration of central vision and severe disability in affected individuals. Clinically, AMD is classified using various methods. One such approach is to categorize the disease as early-stage to late-stage (advanced AMD). Advanced AMD is divided into two types: nonexudative or atrophic AMD (dry AMD) and exudative or neovascular AMD (wet AMD).
Some of the Key Highlights from Dry Age-related Macular Degeneration Pipeline Report
• Over 40+ Dry Age-related Macular Degeneration pipeline therapies are in various stages of growth, and their anticipated acceptance in the Dry Age-related Macular Degeneration market would significantly increase market revenue.
• Leading Dry Age-related Macular Degeneration companies such as Alkeus Pharmaceuticals, Dobecure, Iveric Bio, Mitotech, Stealth BioTherapeutics, Allergo Ophthalmics, Gyroscope Therapeutics, Gemini Therapeutics, Luxa Biotechnology, CHABiotech CO., Ltd, Regenerative Patch Technologies, Lineage Cell Therapeutics, Janssen Research & Development, Belite Bio, Katairo, Cognition Therapeutics, Eye Co Pty Ltd, Applied Genetic Technologies Corporation (AGTC), Aviceda Therapeutics, Kodiak Sciences, Ascentage Pharma, OliX Pharmaceutical, Nanoscope Therapeutics, Inc., Biophytis, Eyestem, Eyevensys, SanBio, Beta Therapeutics, MacRegen, Amarna Therapeutics, MeiraGTx, Cognition Therapeutics, Ocugen, Catalyst Biosciences, Endogena Therapeutics, Oculogenex, Clover Therapeutics, Retrotope, Stuart Therapeutics, Surrozen, 4D Pharma, Ocular Therapeutix, and others are evaluating novel Dry Age-related Macular Degeneration treatment drugs candidate to improve the treatment landscape.
• Key Dry Age-related Macular Degeneration pipeline therapies in various stages of development include ALK-001, Etamsylate, Zimura, Visomitin, Elamipretide, Risuteganib, GT005, GEM1003, RPESC-RPE-4W, MA09-hRPE, CPCB-RPE1, OpRegen, AAVCAGsCD59, Tinlarebant (LBS-008), Remofuscin, CT1812, Fludrocortisone acetate, Complement factor H, AVD-104, KSI-601, Alrizomadlin, OLX301A, MCO-030, BIO-201, Eyecyte-RPE, EYS809, SB 623, BT-2180, Mitia, AMA004, OCU410, IVT CB 2782-PEG, CTX010, CTX020, RT011, 4P-020, Research Programme: Dry Age-related Macular Degeneration (dAMD), Research programme: regenerative therapeutics and others.
• Out of the emerging Dry Age-related Macular Degeneration therapies Eyecyte RPE (Eyestem), OLX301A (OliX Pharmaceuticals), and EYS809 (Eyevensys) are in the early stages of development for Dry AMD treatment.
• On January 13, 2022, ONL Therapeutics, announced that it had closed on its second tranche of the Company's Series B financing. The total proceeds raised in Series B was USD 46.9 million upon Achieving ONL1204 Development Milestones. The company is advancing ONL1204 into open-angle glaucoma and GA associated with dry AMD.
Request a sample and discover the recent advances in Dry Age-related Macular Degeneration therapies @ https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Dry Age-related Macular Degeneration Pipeline Analysis: Drug Profile
ALK-001: Alkeus Pharmaceuticals
ALK-001 is a once-daily oral drug candidate in Phase III clinical trials for the treatment of geographic atrophy (advanced form of AMD) and Stargardt disease. Toxic vitamin A aggregates known as "dimers" are known to form rapidly in Stargardt due to a genetic defect or to accumulate with age in the case of dry AMD. These toxic dimers have been linked to the retinal degeneration seen in Stargardt and AMD. Dimers are formed when two molecules of vitamin A combine chemically. ALK-001 is a vitamin A derivative that has been chemically modified to prevent dimerization.
Zimura: Iveric bio
Zimura (avacincaptad pegol) is an investigational drug that targets and inhibits complement protein C5 cleavage and the formation of its downstream fragments, C5a and C5b. Zimura is thought to reduce or slow the chronic inflammation and cell death associated with the retinal ageing process by inhibiting the formation of membrane attack complex (MAC) and inflammasome activity, potentially avoiding or slowing the degeneration of retinal pigment epithelial cells.
Gain more knowledge on emerging Dry Age-related Macular Degeneration drugs @ https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
DRY AMD Pipeline Therapies and Key Companies
• Zimura: IVERIC bio
• ALK-001: Alkeus Pharmaceuticals
• GT005: Gyroscope Therapeutics
• Risuteganib: Allegro Ophthalmics
• GEM103: Gemini Therapeutics
• CPCB-RPE1: Regenerative Patch Technologies
• RPESC RPE 4W: Luxa Biotechnology
• Eyecyte RPE: Eyestem
• OLX301A: OliX Pharmaceuticals
• EYS809: Eyevensys
Learn more about the FDA approved Dry Age-related Macular Degeneration therapies and Dry Age-related Macular Degeneration Clinical Trials @ https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Dry Age-related Macular Degeneration Pipeline Therapeutics Assessment
By Product Type
• Monotherapy
• Combination Therapy
By Stage
• Discovery
• Pre-Clinical
• Phase I
• Phase II
• Phase III
• Pre-registration
By Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
By Molecule Type
• Monoclonal Antibodies
• Peptides
• Polymers
• Small Molecule
• Gene Therapy
Got queries? Reach out for more information on Dry Age-related Macular Degeneration therapeutics: https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Dry AMD Pipeline Report
Coverage: Global
Key Dry Age-related Macular Degeneration Companies: Alkeus Pharmaceuticals, Dobecure, Iveric Bio, Mitotech, Stealth BioTherapeutics, Allergo Ophthalmics, Gyroscope Therapeutics, Gemini Therapeutics, Luxa Biotechnology, CHABiotech CO., Ltd, Regenerative Patch Technologies, Lineage Cell Therapeutics, Janssen Research & Development, Belite Bio, Katairo, Cognition Therapeutics, Eye Co Pty Ltd, Applied Genetic Technologies Corporation (AGTC), Aviceda Therapeutics, Kodiak Sciences, Ascentage Pharma, OliX Pharmaceutical, Nanoscope Therapeutics, Inc., Biophytis, Eyestem, Eyevensys, SanBio, Beta Therapeutics, MacRegen, Amarna Therapeutics, MeiraGTx, Cognition Therapeutics, Ocugen, Catalyst Biosciences, Endogena Therapeutics, Oculogenex, Clover Therapeutics, Retrotope, Stuart Therapeutics, Surrozen, 4D Pharma, Ocular Therapeutix, and others
Key Dry Age-related Macular Degeneration Pipeline Therapies: ALK-001, Etamsylate, Zimura, Visomitin, Elamipretide, Risuteganib, GT005, GEM1003, RPESC-RPE-4W, MA09-hRPE, CPCB-RPE1, OpRegen, AAVCAGsCD59, Tinlarebant (LBS-008), Remofuscin, CT1812, Fludrocortisone acetate, Complement factor H, AVD-104, KSI-601, Alrizomadlin, OLX301A, MCO-030, BIO-201, Eyecyte-RPE, EYS809, SB 623, BT-2180, Mitia, AMA004, OCU410, IVT CB 2782-PEG, CTX010, CTX020, RT011, 4P-020,Research Programme: Dry Age-related Macular Degeneration (dAMD), Research programme: regenerative therapeutics, and others
Table of Contents
1. Dry Age-related Macular Degeneration Pipeline Report Introduction
2. Dry Age-related Macular Degeneration Pipeline Report Executive Summary
3. Dry Age-related Macular Degeneration Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Dry Age-related Macular Degeneration Pipeline Therapeutics
6. Dry Age-related Macular Degeneration Pipeline: Late Stage Products (Pre-registration)
7. Dry Age-related Macular Degeneration Pipeline: Late Stage Products (Phase III)
8. Dry Age-related Macular Degeneration Pipeline: Mid Stage Products (Phase II)
9. Dry Age-related Macular Degeneration Pipeline: Early Stage Products (Phase I)
10. Dry Age-related Macular Degeneration Pipeline Therapeutic Assessment
11. Inactive Products in the Dry Age-related Macular Degeneration Pipeline
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Dry AMD Companies
14. Key Products in the Dry Age-related Macular Degeneration Pipeline
15. Dry AMD Unmet Needs
16. Dry AMD Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix
Got queries? Reach out for more information on Dry Age-related Macular Degeneration Pipeline Assessment: https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Related Reports:
Primordial Dwarfism Market
https://www.delveinsight.com/report-store/primordial-dwarfism-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
DelveInsight's "Primordial Dwarfism Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Primordial Dwarfism, historical and forecasted epidemiology as well as the Primordial Dwarfism market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Breast Pumps Market
https://www.delveinsight.com/report-store/breast-pumps-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Breast Pumps Market By Technology Type (Manual, Electric, And Battery), By Sales Channel (Online And Offline), and by geography are expected to grow at a steady CAGR forecast till 2027 owing to surge in the number of employed mothers and technological advancements in the product offering.
Hyperuricemia Market
https://www.delveinsight.com/report-store/hyperuricemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
DelveInsight's "Hyperuricemia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hyperuricemia, historical and forecasted epidemiology as well as Hyperuricemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Helicobacter Pylori (H. pylori) Infection Market
https://www.delveinsight.com/report-store/helicobacter-pylori-h-pylori-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
DelveInsight's "Helicobacter Pylori (H. pylori) Infection Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Helicobacter Pylori (H. pylori) Infection, historical and forecasted epidemiology as well as the Helicobacter Pylori (H. pylori) Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
AIDS Dementia- Market
https://www.delveinsight.com/report-store/aids-dementia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
DelveInsight's "AIDS Dementia- Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the AIDS Dementia, historical and forecasted epidemiology as well as the AIDS Dementia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Latest Reports by DelveInsight
Basal Cell Carcinoma Market
https://www.delveinsight.com/report-store/basal-cell-carcinoma-basal-cell-epithelioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Lupus Nephritis Market
https://www.delveinsight.com/report-store/lupus-nephritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Severe Hypertriglyceridemia (SHTG) Market
https://www.delveinsight.com/report-store/severe-hypertriglyceridemia-shtg-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Arthralgia Market
https://www.delveinsight.com/report-store/arthralgia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: info@delveinsight.com
Website: https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which provides benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Dry Age-related Macular Degeneration Pipeline Report 2024 - Clinical Trials, FDA, EMA, & PMDA Approvals, Drugs, Therapeutic Analysis, and Companies by DelveInsight here
News-ID: 3423587 • Views: …
More Releases from DelveInsight Business Research
Global Advanced Melanoma Pipeline Accelerates With 60+ Emerging Therapies, Revea …
DelveInsight's "Advanced Melanoma Pipeline Insight 2025" report delivers an in-depth analysis of more than 55 companies and over 60 investigational therapies currently advancing through the Advanced Melanoma research landscape. It offers detailed profiles of both clinical- and preclinical-stage candidates and provides a thorough evaluation of therapies based on product type, development stage, route of administration, and molecule class. The report also outlines inactive or discontinued programs within this domain.
Explore the…
Global Spasticity Treatment Landscape Set for Transformation: DelveInsight Unvei …
DelveInsight's "Spasticity Pipeline Insight, 2025" report offers an in-depth evaluation of 10+ companies and more than 12 investigational therapies currently advancing through the Spasticity treatment pipeline. The report includes detailed profiles of clinical- and preclinical-stage candidates, along with a thorough assessment of therapies by product type, development phase, route of administration, and molecular class. It also highlights discontinued and inactive programs in the field.
Stay informed with the latest developments! Access…
Lewy Body Dementia Treatment Market 2034 - Market Size, Competitive Landscape, C …
The Lewy Body Dementia (LBD) market across the seven major markets (7MM) was valued at approximately USD 670 million in 2022, with strong growth anticipated through 2034. In 2022, an estimated 11 million dementia cases were recorded across the 7MM, of which ~0.6 million were attributed to Lewy Body Dementia. Rising disease prevalence-driven by aging demographics, enhanced diagnostic capabilities, and increasing awareness-is expected to stimulate market expansion. Companies including EIP…
Bronchitis Treatment Market 2034: Market Size, Competitive Landscape, Companies, …
The bronchitis therapeutics market is projected to grow steadily from 2025-2034, driven by rising disease prevalence, technological progress, and the emergence of new treatment options. Current management focuses on symptom relief through bronchodilators, corticosteroids, and antibiotics for acute cases, while chronic bronchitis requires long-term inhaled therapies, pulmonary rehabilitation, and lifestyle changes. A key advancement is the FDA-approved OHTUVAYRE (ensifentrine), which offers dual bronchodilator and anti-inflammatory benefits. Despite progress, there is…
More Releases for Dry
Rising Prevalence Of Dry Eye Conditions Boosts Growth In Dry Eye Products Market …
The Dry Eye Products Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Dry Eye Products Market Size During the Forecast Period?
In recent years, there has been a significant expansion in the market size of dry eye products. The market is projected…
Dry Powder Inhalers Market - Breathe Freely: Dry Powder Inhalers Empowering Asth …
Newark, New Castle, USA: The "Dry Powder Inhalers Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Dry Powder Inhalers Market: https://www.growthplusreports.com/report/dry-powder-inhalers-market/8762
This latest report researches the industry structure,…
Dry Eye Market - Advancing Eye Wellness: Dry Eye Solutions Revolutionizing Relie …
Newark, New Castle, USA - new report, titled Dry Eye Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Dry Eye market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Dry Eye market. The report offers an overview of the market, which…
Dry Lubricants Market Size to Hit $ 813.78 Million by 2028 | Dry Lubricants Indu …
According to our experience research team, Dry Lubricants Market was valued at USD 755.42 Million in 2021, and the global Dry Lubricants industry is projected to reach a value of USD 813.78 Million by 2028, at a CAGR of 1.2% during the forecast period 2022-2028
The report is focused on gaining various Dry Lubricants market trends, dynamics, growth drivers, opportunities, weaknesses, strengths, and threats restraining the market growth. Further, the global…
Dry Ice Market In-Depth Analysis | Key Participants Dry Ice Corp., Dry Ice UK Lt …
Demand for dry ice is expected to magnify with the development of dry ice machines industry across the globe. Manufacturers in large multinational organizations and private firms have been contributing prominently in the revenue growth of dry ice market. Dry ice being a cost-effective product is expected to bolster its demand across various applications in the near future. Rising number of fire accidents leads to increasing demand for dry ice,…
Dry Screw Vacuum Pumps
Swam Dry vacuum pumps are the latest development in the vacuum pump industry. They offer a number of advantages over traditional vacuum pump designs. Best process gas blowers. There is “NO OIL / NO WATER” contact with the process vapours, which is why they are considered extremely environmentally friendly.
Visit us for more info - http://swamatics.com/ProductDetails.aspx?prod=Process%20Gas%20Blowers/Gas%20Boosters
The definition of a dry vacuum pump is a pump that does not use any…
